Loading provider…
Loading provider…
Infectious Disease Physician in Walnut Creek, CA
NPI: 1437231537Primary Practice Location
JOHN MUIR MEDICAL CENTER - WALNUT CREEK CAMPUS
1601 Ygnacio Valley Rd, Walnut Creek, CA
Primary Employer
Bass Medical Group
bassmedicalgroup.com
HQ Phone
Get MD Bhavna's Phone Numberphone_androidMobile
Get MD Bhavna's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
2003 - 2027
IL State Medical License
2001 - 2004

American Board of Internal Medicine
Infectious Disease
University of California Davis Health
Fellowship • Infectious Disease
2011 - 2012
Southern Illinois University
Residency • Internal Medicine
2001 - 2004
Government Medical College Amritsar
Medical School
Until 2000
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 286 | 636 |
| 2 | 99223Initial hospital inpatient care, typically 70 minutes per day | 122 | 127 |
| 3 | 99291Critical care delivery critically ill or injured patient, first 30-74 minutes | 60 | 125 |
| 4 | 99214Established patient office or other outpatient visit, 30-39 minutes | 27 | 42 |
| 5 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 26 | 32 |
Importance of a specific amino acid pairing for murine MLL leukemias driven by MLLT1/3 or AFF1/4.
Authors: Charles Hemenway
Publication Date: 2014-03-28
Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer.
Authors: Rohit Malik
Publication Date: 2016-07-05
Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.
Authors: Dale Bixby
Publication Date: 2014-08-15
Lead Sponsor: Eli Lilly and Company
Collaborators: AbCellera Biologics Inc., Shanghai Junshi Bioscience Co., Ltd.
Intervention / Treatment: DRUG: Placebo, DRUG: LY3819253, DRUG: LY3832479, DRUG: LY3853113
Lead Sponsor: Eli Lilly and Company
Intervention / Treatment: DRUG: Placebo, DRUG: Donanemab
Lead Sponsor: Eli Lilly and Company
Collaborators: GlaxoSmithKline, AbCellera Biologics Inc., Shanghai Junshi Bioscience Co., Ltd., Vir Biotechnology, Inc.
Intervention / Treatment: DRUG: Placebo, DRUG: Bebtelovimab, DRUG: Etesevimab, DRUG: Bamlanivimab, DRUG: VIR-7831